Scientists test novel drug duo to reboot immune system against tough cancers
NCT ID NCT05082259
Summary
This is an early-stage study to find a safe dose and see if a new drug combination can help the immune system fight advanced cancers. It will test the experimental drug ASTX660 together with the immunotherapy pembrolizumab in up to 61 adults with solid tumors that have stopped responding to standard treatments. The main goals are to check the safety of the combination and see if it shows any early signs of shrinking tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cambridge University Hospitals NHS Trust
RECRUITINGCambridge, CB2 0QQ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Royal Marden NHS Foundation Trust - Drug Development Unit
RECRUITINGSutton, SM2 5PT, United Kingdom
Contact Phone: •••-•••-••••
-
The Royal Marsden NHS Foundation Trust - Breast Unit
RECRUITINGSutton, SM2 5PT, United Kingdom
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.